Premium
Older melanoma patients may respond better to anti‐PD1 immunotherapy
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31794
Subject(s) - pembrolizumab , medicine , immunotherapy , melanoma , nivolumab , tumor microenvironment , oncology , expanded access , cancer , metastasis , ipilimumab , cancer research